Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Operations (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Cash from Operations for 4 consecutive years, with 2559563.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 52.61% to 2559563.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 9328842.0 through Dec 2025, down 28.41% year-over-year, with the annual reading at 9328842.0 for FY2025, 28.41% down from the prior year.
  • Cash from Operations for Q4 2025 was 2559563.0 at bioAffinity Technologies, down from 2480298.0 in the prior quarter.
  • The five-year high for Cash from Operations was 376141.0 in Q2 2022, with the low at 2647206.0 in Q2 2025.
  • Average Cash from Operations over 4 years is 1668893.0, with a median of 1629039.0 recorded in 2023.
  • The sharpest move saw Cash from Operations crashed 261.55% in 2023, then surged 30.02% in 2025.
  • Over 4 years, Cash from Operations stood at 1300636.0 in 2022, then decreased by 24.27% to 1616303.0 in 2023, then dropped by 3.77% to 1677161.0 in 2024, then plummeted by 52.61% to 2559563.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 2559563.0, 2480298.0, and 2647206.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.